TransCelerate BioPharma which is an intriguing new big pharma collaboration was recently launched at a US trade show with the intentions of expediting the clinical research process. According to a recent article from Outsourcing-pharma.com , there are “five areas which have been selected for fudging in the area of clinical study: development of a shared user interface for investigator sites, the mutual recognition of site training and qualification, work on risk-based monitoring, clinical data standards, and a system for ensuring the supply of comparator drugs.”
There was some question as to whether or not organizations such as TransCelerate are needed, but this was quickly refuted by interim CEO and former Corporate VP, Science & Technology, Johnson & Johnson, Garry Neil. Dr. Neil shared that most major pharma companies agree that while new medicines need to increase in quantity and value, the industry should also decrease and eliminate unnecessary R&D costs. Furthermore, the group could benefit the industry by complimenting already existing collaborations and increasing efficiency within regimented clinical trial approaches.
To further your knowledge on a potential new paradigm of clinical development as well as read more about TransCelerate, click here.